By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its fourth-quarter revenues increased 19 percent on strong consumables sales. The firm also turned a profit, which was not expected by Wall Street.

Cepheid brought in total revenues of $58.7 million for the three months ended Dec. 31, compared to revenues of $49.2 million for the fourth quarter of 2009. Analysts, on average, had expected $56.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.